Tags: Arthritis | rheumatoid arthritis | arthritis drug | sarilumab | joint damage

New Arthritis Drug Prevents Joint Damage

Friday, 22 Nov 2013 12:27 PM


A potential rheumatoid arthritis treatment from French drugmaker Sanofi and its U.S. development partner Regeneron Pharmaceuticals Inc. fared better than a fake drug at improving disease signs and symptoms in a late-stage study.
 
The companies said Friday they saw a statistically significant improvement in patient groups that received their drug, sarilumab, combined with methotrexate compared to those who just received methotrexate and a placebo.
 
About 1,200 patients enrolled in the study. Researchers tested two doses of the drug in adults with active rheumatoid arthritis who were not helped by methotrexate.

Editor's note: 3 Signs You’re Close to a Heart Attack
 
Aside from improving signs and symptoms, the treatment also helped physical function and inhibited joint damage progression, the companies said.
 
Rheumatoid arthritis is a chronic inflammatory disease that affects the joints and destroys soft tissue, cartilage and bone. It represents a major area of research for drug companies because it is chronic, meaning patients will likely take the drugs regularly for a long time.
 
Last year, the Food and Drug Administration approved a new treatment for the disease, Pfizer Inc.'s twice-a-day pill Xeljanz.
 

© Copyright 2015 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

1Like our page
2Share
Health-News
A potential rheumatoid arthritis treatment from French drugmaker Sanofi and its U.S. development partner Regeneron Pharmaceuticals Inc. fared better than a fake drug at improving disease signs and symptoms in a late-stage study. The companies said Friday they saw a...
rheumatoid arthritis,arthritis drug,sarilumab,joint damage
183
2013-27-22
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved